PT Kalbe Farma Tbk. EBIT

The latest EBIT for KLBF.JK is $3.8T as of June 2026. That compares with $3.8T in the prior-year period — up 0.2% year over year. That is above the Healthcare sector average of $110B. Investors often review this figure alongside PT Kalbe Farma Tbk.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, KLBF.JK's EBIT moved from $3.8T to $3.8T — a 0.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in PT Kalbe Farma Tbk.'s operating scale or balance-sheet position.

Against Healthcare companies, KLBF.JK currently prints $3.8T for EBIT, while the sector average sits near $110B. That is roughly 3420.3% above the sector mean. Large gaps often invite a closer look at PT Kalbe Farma Tbk.'s growth, margins, and balance sheet.

A EBIT figure of $3.8T for KLBF.JK is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting KLBF.JK's EBIT ($3.8T), review year-over-year change from $3.8T, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.